[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Chung SD, Wang SM, Lai MK, Huang CY, Liao CH, Huang KH, Pu YS, Chueh SC, Yu HJ: Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int; 2009 Apr;103(8):1047-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy.
  • OBJECTIVE: To evaluate the significance of lymphovascular invasion (LVI) to predict cancer-specific survival (CSS) in patients with renal pelvic urothelial carcinoma (UC).
  • PATIENTS AND METHODS: In all, 76 patients with primary renal pelvic UC were treated by nephroureterectomy (NU).
  • Inclusion criteria included nonmetastatic renal pelvic UC with no previous history of bladder cancer, concomitant ureteric lesion, or neoadjuvant chemotherapy.
  • Age, gender, adrenalectomized or not, pathological T stage, grade, and LVI were examined by univariate and multivariate analyses to determine which were independent risk factors.
  • CONCLUSIONS: Adrenal metastases from primary renal pelvic UCs were rare.
  • The present results suggest that ipsilateral adrenalectomy is not necessary during radical NU for treating patients with renal pelvic UCs.
  • LVI appears to be a better prognostic factor for predicting poor outcome of renal pelvic UC than pT stage or tumour grade when using the current tumour-nodes-metastases staging system.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Apr;103(8):1143 [19338572.001]
  • (PMID = 19076143.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Lin CC, Hsu CH, Pu YS: Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: a two-case study. Anticancer Res; 2006 Jul-Aug;26(4B):3191-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: a two-case study.
  • BACKGROUND: The risk of urothelial carcinoma (UC) is increased in patients with end-stage renal disease.
  • Standard regimens for UC (e.g., M-VAC) carry substantial toxicity, which could be exacerbated in patients with end-stage renal disease receiving kidney transplantation, because of the need to take immunosuppressants for life.
  • Concomitant immunosuppressants were maintained during chemotherapy.
  • RESULTS: From 2003 to 2004, two female renal allograft recipients developed renal pelvis UC with para-aortic and lung metastasis, respectively.
  • The patients remained disease-free for 2 and 1 year, respectively, after completion of the chemotherapy.
  • CONCLUSION: The TP-HDFL regimen showed activity and can be safely used in renal allograft recipients with metastatic UC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Transplantation. Urologic Neoplasms / drug therapy. Urologic Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886656.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Yoshimura K, Arai Y, Fujimoto H, Nishiyama H, Ogura K, Okino T, Ogawa O: Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma. Cancer; 2002 Jun 15;94(12):3150-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of extensive parenchymal invasion pattern in pT3 renal pelvic transitional cell carcinoma.
  • BACKGROUND: Pathologic T3 renal pelvic transitional cell carcinoma exhibits various patterns of invasion.
  • The authors investigated the prognostic impact of three patterns of invasion of pT3 renal pelvic transitional cell carcinoma.
  • METHODS: Of 212 patients who underwent surgery for renal pelvic transitional cell carcinoma, 70 with pT3 disease were eligible for the main analyses.
  • The candidate predictors of prognosis included patient age, gender, lesion laterality, tumor grade, perioperative cisplatin-based systemic chemotherapy, lymph node involvement, vascular involvement, and patterns of invasion.
  • Statistically, pT3 disease without extensive parenchymal invasion had a prognosis similar to that of lower stage disease, and pT3 disease with extensive parenchymal invasion had a prognosis similar to that of pT4 disease.
  • CONCLUSIONS: Extensive parenchymal invasion has a strong prognostic impact in renal pelvic transitional cell carcinoma. pT3 disease should be subclassified into two separate entities, that with and that without extensive parenchymal invasion, in view of prognosis.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115347.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res; 2002 Jun;8(6):1863-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful.
  • EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy.
  • RESULTS: We found that tumor grade and pathological stage were important predictors for metastasis and survival in these patients.
  • The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD.
  • Multivariate analysis indicated that the M:E ratio and E-cadherin expression were independent prognostic factors for disease progression and intravesical recurrence, respectively.
  • CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / blood supply. Kidney Neoplasms / blood supply. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cadherins / metabolism. Disease Progression. Endothelial Growth Factors / genetics. Endothelial Growth Factors / metabolism. Female. Fibroblast Growth Factor 2 / genetics. Fibroblast Growth Factor 2 / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / metabolism. Kidney Pelvis / metabolism. Lymphokines / genetics. Lymphokines / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Survival Rate. Ureter / metabolism. Urinary Bladder / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060629.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


5. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, Chung BH, Yang SC, Hong SJ: Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci; 2008 Jun;23(3):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma.
  • Renal pelvic transitional cell carcinoma (TCC), which invades beyond muscularis into peripelvic fat or the renal parenchyma, is diagnosed as stage pT3 despite its structural complexity.
  • We evaluated the prognostic impact of peripelvic fat invasion in pT3 renal pelvic TCC.
  • Between 1986 and 2004, the medical records on 128 patients who were surgically treated for renal pelvic TCC were retrospectively reviewed.
  • On univariate analysis, sex, age, concomitant bladder tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy, tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not influence the disease-specific survival (p>0.05).
  • In conclusion, peripelvic fat invasion is a strong prognostic factor in pT3 renal pelvic TCC.
  • Thus, systemic adjuvant therapy should be considered in the presence of peripelvic fat invasion, even if the lymph nodes are not involved.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Pelvis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 15;94(12):3150-6 [12115347.001]
  • [Cites] J Urol. 1946 Apr;55:366-72 [21020382.001]
  • [Cites] JAMA. 1971 Nov 8;218(6):845-54 [4939530.001]
  • [Cites] J Urol. 1978 May;119(5):594-7 [660726.001]
  • [Cites] J Urol. 1980 May;123(5):629-31 [7420546.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 1990 Nov 1;66(9):1919-23 [2224787.001]
  • [Cites] J Urol. 1991 Jun;145(6):1159-63 [2033684.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1773-5 [1551062.001]
  • [Cites] Urology. 1995 Dec;46(6):796-800 [7502418.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):738-43 [10505034.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1545-52 [15577672.001]
  • [Cites] J Urol. 2005 Dec;174(6):2120-3; discussion 2124 [16280740.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • (PMID = 18583879.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2526530
  •  go-up   go-down


6. Holmäng S, Thomsen J, Johansson SL: Micropapillary carcinoma of the renal pelvis and ureter. J Urol; 2006 Feb;175(2):463-6; discussion 466-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the renal pelvis and ureter.
  • MATERIALS AND METHODS: A clinical and histopathological review was performed in 943 patients with a neoplasm in the renal pelvis or ureter, diagnosed between 1971 and 1998.
  • All except 4 patients had stage T3 disease or higher.
  • Carcinoma in situ was identified in 64% of cases and vascular invasion was present in 81%.
  • CONCLUSIONS: The prognosis is poor since most patients with MPC of the renal pelvis and ureter initially present with advanced disease.
  • Stage for stage the prognosis is not different from that in nonMPC urothelial cell carcinoma.
  • However, radiotherapy and systemic chemotherapy appear to be ineffective.
  • [MeSH-major] Carcinoma, Papillary. Kidney Neoplasms. Kidney Pelvis. Ureteral Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406972.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Ozsahin M, Ugurluer G, Zouhair A: Management of transitional-cell carcinoma of the renal pelvis and ureter. Swiss Med Wkly; 2009 Jun 27;139(25-26):353-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of transitional-cell carcinoma of the renal pelvis and ureter.
  • Transitional-cell carcinoma of the renal pelvis or ureter is a relatively rare disease.
  • The grade and stage of the disease have the most significant impact on the outcome.
  • The treatment of renal pelvis and ureter tumours is open or laparoscopic surgery varying from conservative to more extensive surgical procedures, i.e. radical nephroureterectomy including removal of the contents of Gerota's fascia with ipsilateral ureter and a cuff of bladder at its distal extent.
  • Most available data are from retrospective studies and surgery is the mainstay of treatment.
  • Chemotherapy and/or radiation therapy are possible adjuvant or primary treatment for selected patients; however, prospective studies are needed to confirm their use.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Ureteral Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Male. Neoplasm Staging. Nephrectomy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562529.001).
  • [ISSN] 1424-7860
  • [Journal-full-title] Swiss medical weekly
  • [ISO-abbreviation] Swiss Med Wkly
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 41
  •  go-up   go-down


8. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Grade and stage of the disease have the most significant impact on survival.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Ureteroscopic and to a certain extent percutaneous surgical approaches are widely used today especially in patients with low grade, low stage disease.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


9. Munakata S, Tahara H, Kojima K, Kishimoto T: Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature. Med Sci Monit; 2007 Apr;13(4):CS47-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary urothelial carcinoma of the renal pelvis: report of a case and review of the literature.
  • BACKGROUND: Micropapillary urothelial carcinoma (MPUC) is a rare variant of urothelial carcinoma (UC), which is often advanced at presentation, and carries poor prognosis.
  • We report a rare case of MPUC of the renal pelvis.
  • She had a mass in the left renal pelvis with massive infiltration in the renal parenchyma.
  • Pathological stage was pT4N2M1.
  • Although she received chemotherapy, she died of disease 14 months after operation.
  • CONCLUSIONS: Here we present a rare case of MPUC arising in the renal pelvis with thorough review of the literature.
  • [MeSH-major] Carcinoma, Papillary / pathology. Kidney Neoplasms / pathology. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392655.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


10. Goel MC, Mahendra V, Roberts JG: Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol; 2003 Mar;169(3):925-9; discussion 929-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous management of renal pelvic urothelial tumors: long-term followup.
  • PURPOSE: We present the long-term outcome of percutaneous resection of renal urothelial tumor.
  • MATERIALS AND METHODS: A total of 24 patients underwent primary percutaneous resection of renal urothelial tumor.
  • Patients with low stage pT0-1 disease were treated primarily with percutaneous surgery.
  • Patients with multi-segmental pelvicaliceal system involvement, stage greater than pT1, high grade histology or additional ureteral tumors were considered for nephroureterectomy.
  • Topical chemotherapy (mitomycin C or epirubicin) was administered via nephrostomy tube or intravesical instillation after Double-J stent (Medical Engineering Corp., New York, New York) insertion.
  • RESULTS: Of the 24 cases 2 had squamous cell carcinoma, 5 had grade III transitional cell carcinoma, 15 had grade I to II transitional cell carcinoma and 2 had no tumor.
  • All patients with high grade disease died of malignancy except one (with no further treatment) and 6 of the 15 patients with low grade noninvasive transitional cell carcinoma underwent nephroureterectomy during followup either due to progression of disease, concomitant tumor or complications.
  • Two patients with solitary kidneys died of renal failure unrelated to malignancy.
  • All excised tracks from patients who underwent nephroureterectomy and the renal fossae were free of tumor on histopathological examination.
  • CONCLUSIONS: Percutaneous resection of transitional cell tumor should be considered primarily in patients with early stage disease excluding tumors crossing caliceal infundibula, ureteropelvic junction tumor, tumor extending over multiple calices and synchronous ureteral tumors.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Endoscopy. Female. Follow-Up Studies. Humans. Kidney Pelvis. Male. Middle Aged. Neoplasm Recurrence, Local. Nephrectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2003 Mar;169(3):936-7 [12576816.001]
  • (PMID = 12576814.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Asmis TR, Reaume MN, Dahrouge S, Malone S: Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC). J Clin Oncol; 2004 Jul 15;22(14_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC).
  • : 4545 Background: SCC of the bladder (SCCB), prostate (SCCP), and kidney (SCCK) remains a therapeutic challenge.
  • Much debate exists in the literature about the ideal course of therapy.
  • Demographic, staging, treatment and outcome data was extracted.
  • The Veterans Administration small cell lung cancer classification of limited and extensive disease was adapted to the genitourinary system(limited:disease localized to the true and false pelvis, extensive:disease beyond the pelvis).
  • RESULTS: 555, 858 and 5066 new cases of primary renal, bladder and prostate cancer respectively, were identified.
  • Surviving patients received similar therapy with transurethral resection of the bladder tumor, platinum chemotherapy, etoposide (4-6 cycles), and radical radiotherapy (56-60 Gray).
  • 2/10 had limited stage.
  • Of these two patients one was treated with platinum chemotherapy and etoposide followed by radical radiotherapy (66 Gray), the other patient had a poor performance status at diagnosis and was treated with palliative hormonal ablation and radiotherapy.
  • Our table illustrates the median survival according to site and stage (SCCB and SCCP combined) at diagnosis.
  • We have found that limited stage SCCB and SCCP, when treated with platinum/etoposide chemotherapy along with radical radiotherapy tends to have a more favourable outcome than that of extensive GUSCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016041.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Manji M, Raja MA, Kerr I, Badawi I: Concurrent chemoradiation therapy (CCRT) with weekly Cisplatin in locally advanced cancer cervix (LACC): Single institution experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):5107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation therapy (CCRT) with weekly Cisplatin in locally advanced cancer cervix (LACC): Single institution experience.
  • We review our experience with use of weekly cisplatin concurrent with radiation therapy (RT) during a three-year period.
  • Demographic details, symptomatology, staging (AJCC), management, and outcome data collected.
  • All patients had external beam radiation therapy (EBRT) 4500 cGy + boost 540 cGy in 28 fractions followed by single application brachytherapy with cesium, delivering 3000 cGy to point A + parametrial boost.
  • Chemotherapy: cisplatin 40 mg/m<sup>2</sup> (30 mg/m<sup>2</sup> if para aortic nodes included in RT) weekly for 5 doses starting with RT.
  • Diagnosis by punch biopsy all patients with 32 squamous cell carcinoma, 1 poorly differentiated carcinoma.
  • Stage IB2:3, IIB:17, IIIB:11, IVA: 2.
  • All patients had normal baseline blood count and renal function.
  • EBRT given to pelvis alone in 23, pelvis + paraaortic nodes in 10.
  • Three interruptions during therapy, 14 short delays.
  • Chemotherapy 11 delays, 3 dose reductions.
  • No grade 3 or 4 hematologic/renal toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gallagher DJ, Milowsky MI, Gerst SR, Tickoo S, Ishill N, Ishill N, Regazzi A, Trout A, Bajorin DF: A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol; 2009 May 20;27(15_suppl):5072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of sunitinib on a continuous dosing schedule in patients (pts) with relapsed or refractory urothelial carcinoma (UC).
  • METHODS: The primary objectives of this single institution phase II study of sunitinib in pts with UC who have failed prior chemotherapy were:.
  • A minimax 2-stage design was used (maximal 32 pts).
  • Primary sites included bladder (28), and renal pelvis (3).
  • Prior therapy included 1 pt with 1 drug, 19 pts with 2, 7 with 3 and 4 with 4.
  • One pt achieved PR, 12 pts had SD, 12 had PD, 2 are too early to assess for response, and 4 patients did not complete cycle 1 (2 related to toxicity, and 2 related to non-treatment-related deaths).
  • Radiographic regression was seen in liver, lung, soft tissue and lymph nodes.
  • Upcoming trials will evaluate sunitinib in combination with standard chemotherapy in pts with UC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive renal pelvis transitional cell carcinoma.
  • : 4694 Background: Upper tract tumors of the renal pelvis and ureter represent a small proportion of patients with transitional cell carcinoma.
  • We report our experience with invasive renal pelvis and proximal ureter transitional cell carcinoma.
  • METHODS: All patients seen at our institution between 1995 and 2003 with renal pelvis and proximal ureter who had adequate follow up were selected.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • RESULTS: The median age was 72(47-92), 2/3 of the patients were men; renal pelvis was the primary site in 21, upper ureter in 3; 13 (54%) were smokers; ten patients (42%)had bladder tumors either preceding the renal pelvis tumor or after; six (25%) of the patients had distant metastases; ten (42%) had nodal metastases;The median overall survival was 27 months.
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Oka H, Shiraishi Y, Negoro H, Iwamura H, Moroi S, Soeda A, Takeuchi H, Kawakita M: [Clinical review of conservative management of upper urinary tract transitional cell carcinoma]. Hinyokika Kiyo; 2006 Apr;52(4):249-53
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of conservative management of upper urinary tract transitional cell carcinoma].
  • We reviewed 18 patients with transitional cell carcinoma of the renal pelvis and ureter undergoing nephron-sparing surgery between April 1990 and Febrary 2003.
  • The tumor site was the renal pelvis in 2, ureter in 13 and ureteral orfice in 2.
  • Eight patients underwent endourological treatment and 10 patients open surgery including partial ureterectomy performed on 8 patient.
  • Among those defined as imperative, the histopathological stage was pT1 in one, pT2 in one, pT3 in 3 and one in pT4.
  • Among the elective cases, the histopathological stage was pTa in 7, pT1 in 2, pT2 in one, pT3 in 2 patients.
  • In the patients with tumors pT2 or higher and/or grade 3, the prognosis was poor which suggests the need for intensive therapy including lymph node dissection and/or adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy / methods. Ureteral Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686350.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol; 2010 Jun;57(6):1072-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
  • BACKGROUND: There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC).
  • MEASUREMENTS: Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma.
  • Tumor location was divided into two groups (renal pelvis and ureter) based on the location of the dominant tumor.
  • When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors.
  • Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%.
  • CONCLUSIONS: There is no difference in outcomes between patients with renal pelvic tumors and with ureteral tumors following nephroureterectomy.
  • These data support the current TNM staging system, whereby renal pelvic and ureteral carcinomas are classified as one integral group of tumors.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Ureter / pathology. Urethral Neoplasms / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19619934.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Deffieux X, Morice P, Thoury A, Camatte S, Duvillard P, Castaigne D: Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma. J Am Coll Surg; 2005 Jan;200(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma.
  • BACKGROUND: To describe characteristics of patients with nodal spread and the anatomy of pelvic and para-aortic node involvement in primary fallopian tube carcinoma.
  • STUDY DESIGN: Between 1985 and 2003, 19 women with primary fallopian tube carcinoma underwent systematic bilateral pelvic and para-aortic lymphadenectomy up to the level of the left renal vein.
  • Initial lymphadenectomy (without chemotherapy) was performed in 6 patients and in 13 patients lymphadenectomies were performed after chemotherapy at the time of second-look operation.
  • CONCLUSIONS: In patients with primary tubal carcinoma, the left para-aortic chain above the level of the inferior mesenteric artery is the most frequently involved.
  • Lymphadenectomy should involve all pelvic and para-aortic chains up to the level of the left renal vein, even in patients with stage I disease.
  • [MeSH-major] Carcinoma / secondary. Fallopian Tube Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aorta, Abdominal. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15631919.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kafé H, Verbavatz JM, Cochand-Priollet B, Castagnet P, Vieillefond A: Collecting duct carcinoma: an entity to be redefined? Virchows Arch; 2004 Dec;445(6):637-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma: an entity to be redefined?
  • Collecting duct carcinomas (CDCs) are highly aggressive tumors with poor survival at 1 year and are often metastatic at the time of diagnosis.
  • It has been shown that patients may have better survival when treated with a chemotherapy regimen used for urothelial carcinoma.
  • The two main differential diagnoses are renal pelvis urothelial carcinoma with infiltration of the kidney and/or high-grade and high-stage papillary renal cell carcinoma.
  • The aim of our study was to compare the immunophenotype of 14 CDCs with 6 renal pelvis urothelial carcinomas (RPUC) infiltrating the medulla.
  • (3) AQP-3 is a marker of interest for improving the histological classification of CDC and unclassified aggressive renal tumors.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Tubules, Collecting

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F13-28 [10644652.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Science. 1992 Apr 17;256(5055):385-7 [1373524.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):111-6 [11815966.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1138-40 [14501710.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8407-12 [9525951.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 2):F663-72 [7503232.001]
  • [Cites] Histopathology. 1985 Oct;9(10):1037-50 [2417930.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • (PMID = 15480763.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / Aquaporins; 0 / Vimentin; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


19. Firat S, Murray K, Erickson B: High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):201-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
  • PURPOSE: To evaluate the role of high-dose whole abdominal and pelvic irradiation (WART) in the treatment of epithelial ovarian carcinoma.
  • METHODS AND MATERIALS: A retrospective review was performed on 71 patients with Stage I-III ovarian carcinoma who were treated with WART using an open field technique after total abdominal hysterectomy and bilateral oophorectomy with or without omentectomy.
  • None of the patients had received chemotherapy before RT.
  • Thirty-one patients received Alkeran or cyclophosphamide and two received cisplatin-based chemotherapy after WART.
  • The median whole abdominal dose was 36 Gy (range 9-45.5), delivered in a median of 30 fractions (range 8-46).
  • The median pelvic dose was 51 Gy (range 16-59).
  • The right lobe and a portion of the left lobe of the liver were shielded with custom blocks at a median dose of 25 Gy (range 9-41).
  • The median dose to the kidneys was 19 Gy (range 4-30).
  • RESULTS: The 5-year overall survival rate was 93%, 48%, and 29% for Stage I, II, and III patients, respectively.
  • On multivariate analysis, stage and the extent of residual disease were independent prognostic factors.
  • For this group, a total abdominal dose of > or /=36 Gy was associated with a longer overall survival independent of stage, grade, and the amount of residual disease.
  • This was most likely due to a significant reduction in the incidence of abdominal recurrence in patients receiving >36 Gy to the whole abdomen (18% vs. 49%, p = 0.006).
  • Twenty-one percent (n = 15) of the patients developed Grade 3 or 4 (Radiation Therapy Oncology Group [RTOG] criteria) chronic small or large bowel toxicity.
  • A whole abdominal dose >30 Gy and a pelvic dose >50 Gy were associated with a significant increase in small bowel obstruction (p = 0.01) independent of other factors.
  • Grade 3 or 4 renal toxicity (RTOG) was observed in 4%, and 2 patients (3%) were diagnosed with pelvic insufficiency fractures that were managed conservatively.
  • CONCLUSION: Survival after RT for ovarian carcinoma rivals that achieved with systemic chemotherapy.
  • Careful attention to balancing toxicity and efficacy is imperative if RT is to have a future role in the treatment of this disease.
  • [MeSH-minor] Abdomen / radiation effects. Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Longitudinal Studies. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pelvis / radiation effects. Prognosis. Radiation Injuries / etiology. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12909234.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital.
  • BACKGROUND: Urothelial carcinoma of the upper urinary tract is relatively rare, occurring in 5% of all urothelial tumors.
  • Ureteral urothelial carcinoma is even less common than that of the renal pelvis, accounting for about 25% of all upper urinary tract tumors.
  • The aim of this study was to evaluate the clinical behavior, survival, recurrence and prognostic information of primary ureteral urothelial carcinoma from our 11 years of experience at the Taipei Veterans General Hospital.
  • METHODS: We retrospectively reviewed 111 patients with ureteral urothelial carcinoma who had been treated in our hospital between January 1993 and December 2003.
  • Tumor staging was according to the 2002 AJCC TNM classification and stage groupings.
  • Patients with stage Oa and stage Ois were categorized as stage Oa/is, and patients with pathologic T stage pTa and pTis were categorized as pTa/is for statistical analysis.
  • Of the 111 patients, 5 presented with stage Oa/is, 38 with stage I, 23 with stage II, 21 with stage III, and 24 with stage IV.
  • Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy or both.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and overall survival.
  • Stage (p = 0.0001), pT (p =0.0001) and grade (p = 0.026) were also significant prognostic factors of recurrence in multivariate analysis.
  • Tumor stage and grade are the only significant prognostic factors for both cancer-specific and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


21. Watanabe M, Hayashi T, Takamatsu M, Kamitani A, Inoue M, Morisue K, Irie S, Kaneshige T: [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment]. Nihon Hinyokika Gakkai Zasshi; 2003 Mar;94(3):428-33
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of renal pelvic and ureteral cancer: prognosis and frequency of subsequent bladder cancer following surgical treatment].
  • PURPOSE: A retrospective investigation of patients presenting with renal pelvic and ureteral cancer was performed.
  • This study focused on the prognostic factors and frequency of subsequent bladder cancer following surgical treatment.
  • MATERIALS AND METHODS: Forty-five patients presenting with transitional cell carcinoma, who had undergone nephroureterectomy at the Department of Urology, Okayama Central Hospital, from March 1990 to November 2000, were reviewed.
  • Seventeen patients exhibited renal pelvic cancer, 25 cases displayed ureteral cancer and three subjects presented with multiple cancers.
  • Eleven patients had received treatment for precedent or coexistent superficial bladder cancer by transurethral resection.
  • CONCLUSIONS: Adjuvant chemotherapy for prevention of clinical metastasis should be considered in cases involving pT3 or higher stage, grade 3, or in instances of pathologically confirmed lymph node metastasis.
  • The significant occurrence of subsequent bladder cancer in the case of tumor multiplicity suggested that prophylactic therapy such as intravesical BCG instillation or chemotherapy might be beneficial.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / etiology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12710077.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report].
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


23. Asmis TR, Reaume MN, Dahrouge S, Malone S: Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int; 2006 Apr;97(4):711-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center.
  • OBJECTIVE: To review patients with genitourinary (GU) small cell carcinoma (SCC) treated at a regional cancer centre, as due to its rarity and aggressive nature, GU SCC remains a therapeutic challenge.
  • Demographic, staging, treatment and outcome data were extracted.
  • The Veterans Administration small cell lung cancer staging classification of "limited" or "extensive" disease was adapted for SCC of the prostate and bladder (with "limited" defined as disease localized to the true and false pelvis, and "extensive" as disease beyond the pelvis).
  • RESULTS: In all, 555, 858 and 5066 new cases of primary renal, bladder and prostate cancer, respectively, were identified.
  • Surviving patients received similar therapy, with transurethral resection of the bladder tumour, platinum-based chemotherapy, etoposide (4-6 cycles), and radical radiotherapy (56-60 Gy).
  • Two of 10 patients with SCC of the prostate had limited-stage disease, but all 10 died, the median survival being 9.5 months.
  • Survival by stage for both types combined was 59 months for limited disease and 8 months for extensive disease.
  • CONCLUSIONS: These results indicate that GU SCC is an aggressive cancer; limited-stage SCC of the bladder or prostate, when treated with platinum/etoposide chemotherapy and radical radiotherapy, has a more favourable outcome than that of extensive GU SCC.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Urogenital Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536759.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A: A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):543-52
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
  • OBJECTIVES: After surgical debulking and volume-directed irradiation of the pelvis/para-aortic lymph nodes, treatment was randomized to compare recurrence-free survival (RFS) and toxicity between two chemotherapy regimens for the treatment of women with advanced stage endometrial carcinoma.
  • METHODS: Treatment was randomized between 6 cycles of cisplatin [C] (50 mg/m(2)) and doxorubicin [D] (45 mg/m(2)) with or without paclitaxel [P] (160 mg/m(2)).
  • RESULTS: Of 659 patients enrolled following surgery, 552 eligible patients were randomized to chemotherapy after irradiation.
  • Accrual closed to Stage IV patients in June, 2003.
  • Approximately 80% completed six cycles of chemotherapy.
  • Three deaths resulted from bowel complications and one death was due to renal failure.
  • The hazard of recurrence or death relative to the CD arm stratified by stage is 0.90 (95% CI is 0.69 to 1.17, p=0.21, one-tail).
  • Stage, residual disease, histology/grade, positive para-aortic node and cytology, pelvic metastases and age were significantly associated with RFS.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108877.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA101165-04; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-22; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS102171; NLM/ PMC4459781
  •  go-up   go-down


25. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • RESULTS: Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma.
  • The tumors were located in the renal pelvis in 10 and the ureter in 6.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Fifteen of the tumors were pathologic Stage T3 or worse.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • CONCLUSIONS: Primary nonurothelial carcinomas of the renal pelvis and ureter are rare.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Pryma DA, Akhurst T: Hydronephrotic ectopic pelvic kidney simulates sacral metastasis from breast cancer. Clin Nucl Med; 2005 Apr;30(4):244-5
Genetic Alliance. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 57-year-old woman with a history of a right modified radical mastectomy after neoadjuvant chemotherapy for stage IIIB infiltrating ductal breast carcinoma presented for follow-up bone scan.
  • Initial inspection was suspicious for sacral metastasis, but on closer review the absence of renal activity in the left flank was noted.
  • [MeSH-major] Hydronephrosis / radionuclide imaging. Kidney / abnormalities. Kidney / radionuclide imaging. Pelvis / radionuclide imaging. Sacrum / radionuclide imaging
  • [MeSH-minor] Breast Neoplasms / radiography. Breast Neoplasms / radionuclide imaging. Carcinoma, Ductal / radiography. Carcinoma, Ductal / radionuclide imaging. Carcinoma, Ductal / secondary. Diagnosis, Differential. Female. Humans. Middle Aged. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764880.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol; 2010 Oct;58(4):574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious.
  • Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded.
  • Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor.
  • On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p=0.01).
  • Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18).
  • On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2).
  • On multivariate analysis, pathologic stage (p<0.0001) and nodal status (p=0.01) were associated with worse CSS.
  • CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):612-8 [19075275.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):794-802 [18207313.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):438-44 [16115524.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Urology. 1997 Sep;50(3):321-9 [9301692.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [CommentIn] Eur Urol. 2011 Apr;59(4):e23 [21255908.001]
  • [CommentIn] Eur Urol. 2011 Jan;59(1):e2 [20980096.001]
  • [CommentIn] J Urol. 2011 Feb;185(2):463 [22088622.001]
  • (PMID = 20637540.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS628548; NLM/ PMC4174409
  •  go-up   go-down


28. Karam A, Feldman N, Holschneider CH: Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy. Nat Clin Pract Oncol; 2007 Jun;4(6):375-80
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A biopsy of the mass revealed a poorly differentiated squamous-cell carcinoma of the cervix.
  • An MRI study of the abdomen and pelvis showed a 4 cm cervical mass that was suspicious for left parametrial and rectovaginal septal involvement.
  • INVESTIGATIONS: General physical and gynecological examinations, cervical biopsy, pelvic and obstetric ultrasound, histopathological examination, MRI of the abdomen and pelvis without and with gadolinium, neonatal hearing test and renal function studies.
  • DIAGNOSIS: Poorly differentiated stage IB2 squamous-cell carcinoma of the cervix with MRI imaging suggestive of parametrial and rectovaginal septal involvement.
  • MANAGEMENT: Neoadjuvant chemotherapy using weekly cisplatin from 24 to 30 weeks, bed rest and oral terbutaline at 31 weeks because of premature contractions, and a course of antenatal steroids to promote fetal lung maturity.
  • At 33 weeks radical cesarean hysterectomy, bilateral pelvic and para-aortic lymphadenectomy and bilateral ovarian transposition were carried out, followed by adjuvant pelvic radiation therapy with cisplatin chemosensitization 4 weeks postpartum.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Hysterectomy. Pregnancy Complications, Neoplastic / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Cesarean Section. Female. Humans. Neoadjuvant Therapy. Pregnancy. Treatment Outcome


29. Zetola-Burneo N, Brown C: Cases from the Osler Medical Service at Johns Hopkins University. Am J Med; 2004 Feb 1;116(3):198-200
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old white woman with a history of stage III squamous cell carcinoma of the anus was transferred to Johns Hopkins Hospital for further evaluation of renal failure, hemolytic anemia, and thrombocytopenia.
  • The patient was first diagnosed with squamous cell carcinoma of the anus 1 year before admission.
  • She was treated with external beam radiation of the pelvis and two cycles of mitomycin C-based chemotherapy (a cumulative dose, 34 mg/m(2)).
  • Three months before admission, the patient developed dysuria.
  • A renal ultrasound and an abdominal computed tomographic scan showed no abnormalities or obstruction.
  • There was no radiographic or clinical evidence of relapse of her squamous cell carcinoma.
  • [MeSH-minor] Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14749166.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


30. Serkies K, Jassem J: Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity. Int J Radiat Oncol Biol Phys; 2004 Nov 1;60(3):814-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Locally advanced or high-risk early-stage cervical cancer patients treated with RT and concurrent weekly cisplatin at a dose of 40 mg/m(2) i.v. (maximum dose, 70 mg) for five cycles.
  • Definitive RT included whole pelvis external beam RT to the International Commission on Radiation Units and Measurements reference dose of 40 Gy plus a 10-Gy boost to the parametrium and two brachytherapy applications of 20 Gy to point A each.
  • Postoperative RT consisted of pelvic external beam RT to the International Commission on Radiation Units and Measurements reference dose of 50 Gy and one brachytherapy application of 30 Gy at a depth of 0.5 cm from the applicator surface.
  • Definitive RT was administered to 57 International Federation of Gynecology and Obstetrics "bulky" Stage IB or IIB-IVA patients, and 53 patients underwent postoperative RT; 2 patients underwent RT for stump carcinoma.
  • All but 2 patients (both administered definitive RT) completed RT.
  • Of the 112 patients, 62 (55%) did not undergo the planned five cycles of cisplatin because of treatment toxicity (n = 35; 31%) or noncompliance with the treatment schedule because of delayed administration of the first cycle or omission of a cycle for reasons other than toxicity (n = 23; 21%).
  • The most common side effects resulting in chemotherapy discontinuation included GI complications (n = 7) and impaired renal function (n = 5).
  • Furthermore, a number of patients were unable to comply with the treatment schedule owing to reasons unrelated to treatment toxicity.
  • Thus, administration of the full chemotherapy dose may be difficult, although the delivery of planned RT was generally not compromised.
  • Additional follow-up is needed to assess the late toxicity of combined modality treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. Patient Compliance. Radiation-Sensitizing Agents / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Humans. Kidney Diseases / chemically induced. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15465198.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Harshman LC, Srinivas S, Kamaya A, Chung BI: Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol; 2009 Jun;6(6):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Noncontrast CT of the abdomen and pelvis revealed a 9.1 cm right renal mass.
  • INVESTIGATIONS: Contrast CT of the chest, abdomen and pelvis, MRI of the abdomen and pelvis with gadolinium, radionuclide bone scan, lung nodule biopsy, complete blood count, comprehensive metabolic profile, and measurement of serum lactate dehydrogenase.
  • DIAGNOSIS: Stage IV, T3bN0M1 clear cell renal cell carcinoma, with an associated tumor thrombus extending into the vena cava.
  • MANAGEMENT: The patient was treated with neoadjuvant sunitinib, which resulted in a marked response in the primary tumor and metastatic lesions as well as regression of the tumor thrombus well into the renal vein.
  • She was restarted on sunitinib with resultant disease stabilization, but discontinued the drug owing to toxicity.
  • [MeSH-major] Indoles / therapeutic use. Kidney Neoplasms / therapy. Nephrectomy. Pyrroles / therapeutic use. Thrombosis / therapy. Vascular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19498412.001).
  • [ISSN] 1759-4820
  • [Journal-full-title] Nature reviews. Urology
  • [ISO-abbreviation] Nat Rev Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down






Advertisement